MAPT and cerebrovascular disorder: Alzheimer’s disease (AD) pathologic changes (e.g. amyloid and tau aggregation), and cerebrovascular disease (CVD) often coexist, and there is a growing body of literature supporting that pathologic changes and imaging features of CVD contribute to cognitive decline1–6.